Norepinephrine in neurological disorders

Brain Norepinephrine: Neurobiology and Therapeutics

Volumn , Issue , 2007, Pages 436-471

  Fornai, Francesco ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84932613327     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511544156.016     Document Type: Chapter

References (80)

1. Dahlstroem, A. and Fuxe, K. Evidence for the existence of monoamine neurons in the central nervous system. Acta Physiol. Scand., 64 (1965), 1-36.
2. Woulfe, J. M., Fluferfelt, B. A. and Hrycyshyn, A.W. Efferent connections of the A1 noradrenergic cell group: a DBH immunohistochemical and PHA-L anterograde tracing study. Exp. Neurol., 109 (1990), 308-322.
3. Brodal, A. (Ed.). The reticular formation and some related nuclei. In Neurological Anatomy in Relation to Clinical Medicine. (New York: Oxford University Press, 1981), pp. 394-447.
4. Foote, S. L., Bloom, F. E. and Aston-Jones, G. Nucleus locus coeruleus: new evidence of anatomical and physiological specificity. Physiol. Rev., 63 (1983), 844-914.
5. Aston-Jones, G., Chiang, C. and Alexinski, T. Discharge of noradrenergic locus coeruleus neurons in behaving rats and monkeys suggests a role in vigilance. In Progress in Brain Research, Vol. 88, ed. C. D. Barnes and O. Pompeiano. (Amsterdam: Elsevier, 1991), pp. 501-520.
6. Bing, G., Filer, D., Miller, J. C. and Stone, E. A. Noradrenergic activation of immediate early genes in rat cerebral cortex. Mol. Brain Res., 11 (1991), 43-46.
7. Cirelli, C., Pompeiano, M. and Tononi, G. Neuronal gene expression in the waking state: a role for the locus coeruleus. Science, 274 (1996), 1212-1215.
8. Nagai, T., Satoh, K., Immamoto, K. and Maeda, T. Divergent projections of catecholamine neurons of the locus coeruleus as revealed by fluorescent retrograde double labeling technique. Neurosci. Lett., 23 (1981), 117-123.
9. Harik, S. I. and McGunigal, T., Jr. The protective influence of the locus ceruleus on the blood-brain barrier. Ann. Neurol., 15: 6 (1984), 568-574.
10. Reading, P. J. and Dunnett, S. B. 6-Hydroxydopamine lesions of nigrostriatal neurons as an animal model of parkinson's disease. In Toxin-induced Models of Neurological Disorders, ed. M. L.Woodruff and A. J. Nonneman. (New York: Plenum Press, 1994), pp. 89-119.
11. Lidbrink, P. and Jonsson, G. Noradrenaline nerve terminals in the cerebral cortex: effects on noradrenaline uptake and storage following axonal lesion with 6-hydroxydopamine. J. Neurochem., 22 (1974), 617-626.
12. Luthman, J., Fredriksson, A., Sundstrom, E., Jonsson, G. and Archer, T. Selective lesion of central dopamine or noradrenaline neuron system in the neonatal rat: motor behaviour and monoamine alterations at adult stage. Behav. Brain Res., 33 (1989), 267-277.
13. Mavridis, M., Degryse, A.D., Lategan, A. J., Marien, M. R. and Colpaert, F. C. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience, 41 (1991), 507-523.
14. Forno, L. S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol., 55 (1996), 259-272.
15. Ehringer, H. and Hornykiewicz, O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr verhalten bei Erkrankungen des Extrapyramidalen Systems. Klin. Wschr., 38 (1960), 1236-1239.
16. German, D. C., Manaje, K. F., White, C. L. et al. Disease specific pattern of locus coeruleus cell loss. Ann. Neurol., 32 (1992), 667-676.
17. Mann, D. M. The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system. Mech. Ageing Dev., 23 (1983), 73-94.
18. Bertrand, E., Lechowicz, W., Szpak, G. M. and Dymecki, J. Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease. Folia Neuropathol., 35 (1997), 80-86.
19. Gaspar, P., Duickaerts, C., Alvarez, C., Javoy-Agid, F. and Berger, B. Alterations of dopaminergic and noradrenergic innervations in motor cortex of Parkinson's disease. Ann. Neurol., 30 (1991), 365-374.
20. Hornykiewicz, O. and Pifl, C. The validity of the MPTP primate model for neurochemical pathology of idiopathic Parkinson's disease. In Noradrenergic Mechanisms in Parkinson's Disease, ed. M. Briley and M. Marien. (Boca Raton: CRC Press, 1994), pp. 59-71.
21. Gerlach, M. and Riederer, P. The pathophysiological basis of Parkinson's disease. In Series of New Drugs, Vol. 1. Inhibitors of Monoamine Oxidase B, ed. I. Szlenyi. (Basel: Birkhauser, 1993), pp. 25-50.
22. Chan-Palay, V. and Asan, E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer's type and in Parkinson's diseasewith andwithout dementia and depression. J. Comp. Neurol., 287 (1989), 373-392.
23. Dooneief, G., Mirabello, E., Bell, K. et al. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch. Neurol., 49 (1992), 305-307.
24. Takahashi, A. Autonomic nervous system disorders in Parkinson's disease. Eur. Neurol., 31 (Suppl.1): (1991) 141-147.
25. Stein, Y., Mayeux, L. and Cote, L. Reaction time and vigilance in Parkinson's disease: possible role of altered norepinephrine metabolism. Arch. Neurol., 41 (1984), 1086-1089.
26. Forno, L. S., Langston, J.W., DeLanney, L. E., Irwin, I. and Ricaurte, G. A. Locus coeruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann.Neurol., 20 (1986), 449-455.
27. Seniuk, N. A., Tatton, W. G. and Greenwood, C. E. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res., 27 (1990), 7-20.
28. Gesi, M., Soldani, P., Giorgi, F. S. et al. The role of the locus coeruleus in the development of Parkinson's disease. Neurosci. Biobehav. Rev., 24 (2000), 655-668.
29. Fornai, F., Bassi, L., Torracca, M. T., Scalori, V. and Corsini, G.U. Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice. Eur. J. Pharmacol., 283 (1995), 99-102.
30. Marien, M., Briley, M. and Colpaert, F.Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur. J. Pharmacol., 236 (1993), 487-489.
31. Sonsalla, P. K., Giovanni, A., Sieber, B. A., Delle Donne, K. and Manzino, L. Characteristics of dopaminergic neurotoxicity produced by MPTP and methamphetamine. Ann. N. Y. Acad. Sci., 648 (1992), 229-238.
32. Fornai, F., Torracca, M. T., Bassi, L. et al. Norepinephrine loss selectively enhances chronic nigrostriatal dopamine depletion in mice and rats. Brain Res., 735 (1996), 349-353.
33. Kamisaki, Y., Hamahashi, T., Hamada, T., Maeda, K. and Itoh, T. Presynaptic inhibition by clonidine of neurotransmitter amino acid release in several brain regions. Eur. J. Pharmacol., 217 (1992), 57-63.
34. Fornai, F., Giorgi, F. S., Alessandrì, M. G., Giusiani, M. and Corsini, G.U. Effects of pretreatment with DSP-4 on methamphetamine-induced striatal dopamine losses and pharmacokinetics. J. Neurochem., 72 (1999), 777-784.
35. Arnold, P. S., Racine, R. J. andWise, P. A. Effects of atropine, reserpine, 6-hydroxydopamine and handling on seizure development in the rat. Exp. Neurol., 40 (1973), 457-470.
36. McIntyre, D. C. and Edson, N. Facilitation of amygdala kindling after norepinephrine depletion with 6-hydroxydopamine. Exp. Neurol., 74 (1981), 748-757.
37. Corcoran, M. E. and Mason, S. T. Role of forebrain catecholamines in amygdaloid kindling. Brain Res., 190 (1980), 473-484.
38. Altman, I. M. and Corcoran, M. E. Facilitation of neocortical kindling by depletion of forebrain noradrenaline. Brain Res., 270 (1983), 174-177.
39. McIntyre, D. C., Edson, N., Chao, G. and Knowles, V. Differential effect of acute vs chronic desmethylimipramine on the rate of amygdala kindling in rats. Exp. Neurol., 78 (1982), 158-166.
40. Jimenez-Rivera, C., Voltura, A. andWeiss, G. K. Effect of locus coeruleus stimulation on the development of kindled seizures. Exp. Neurol., 95 (1987), 13-20.
41. McIntyre, D. C. andWong, R. K. Cellular and synaptic properties of amygdala-kindled pyriform cortex in vitro. J. Neurophysiol., 55 (1986), 1295-1307.
42. Mason, S. T. and Corcoran, M. E. Catecholamines and convulsions. Brain Res., 170 (1979), 497-507.
43. Sullivan, H. C. and Osorio, I. Aggravation of penicillin-induced epilepsy in rats with locus coeruleus lesions. Epilepsia, 32 (1991), 591-596.
44. Giorgi, F. S., Ferrucci, M., Lazzeri, G. et al. A damage to locus coeruleus neurons converts sporadic seizures into self-sustaining limbic status epilepticus. Eur. J. Neurosci., 17 (2003), 2593-2601.
45. Piredda, S. and Gale, K. A crucial epileptogenic site in the deep prepyriform cortex. Nature, 317 (1985), 623-625.
46. Krahl, S. E., Clark, K. B., Smith, D. C. and Browning, R. A. Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation. Epilepsia, 39 (1998), 709-714.
47. Weinshenker, D. and Szot, P. The role of catecholamines in seizure susceptibility: new results using genetically engineered mice. Pharmacol. Ther., 94 (2002), 213-233.
48. Browning, R. A., Wade, D. R., Marcinczyk, M., Long, G. L. and Jobe, P. C. Regional brain abnormalities in noreprinephrine uptake and dopamine beta-hydroxylase activity in the genetically epilepsy-prone rat. J. Pharmacol. Exp. Ther., 249 (1989), 229-235.
49. Szot, P., Weinshenker, D., White, S. S. et al. Norepinephrine-deficient mice have increased susceptibility to seizure-inducing stimuli. J. Neurosci., 19 (1999), 10 985-10 992.
50. Zuscick, M. J., Sands, S., Ross, S. A. et al. Overexpression of the α1B adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy. Nature Med., 6 (2000), 1388-1394.
51. Kunieda, T., Zuscik, M. J., Boongird, A. et al. Systemic overexpression of the alpha 1Badrenergic receptor in mice: an animal model of epilepsy. Epilepsia, 43 (2002), 1324-1329.
52. Battaglia, G., Fornai, F., Buscati, C. L. et al. Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity. J. Neurochem., 86 (2003), 413-421.
53. Janumpalli, S., Butler, L. S., MacMillian, L. B., Limbird, L. E. and McNamara, J.O. A point mutation (D79N) of the alpha2A adrenergic receptor abolishes the antiepileptogenic action of endogenous norepinephrine. J. Neurosci., 18 (1998), 2004-2008.
54. Briere, R., Sherwin, A. L., Robitaille, Y. et al. Alpha-1 adrenoceptors are decreased in human epileptic foci. Ann. Neurol., 19 (1986), 26-30.
55. Pacia, S.V., Doyle, W. K. and Broderick, P. A. Biogenic amines in the human neocortex in patients with neocortical and mesial temporal lobe epilepsy: identification with in situ microvoltammetry. Brain Res., 899: 1-2 (2001), 106-111.
56. Jobe, P. C., Dailey, J.W. and Wernicke, J. F. A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders. Crit.Rev.Neurobiol., 13 (1999), 317-356.
57. Goldstein, D. S., Holmes, C., Cannon, R.O., 3rd, Eisenhofer, G. and Kopin, I. J. Sympathetic cardioneuropathy in dysautonomias. New Engl. J. Med., 336 (1997), 696-702.
58. Scatton, B., Dennis, T., L'Hereux, R. et al. Degeneration of noradrenergic and serotoninergic but not dopaminergic neurons in the lumbar spinal cord of parkinsonian patients. Brain Res., 380 (1986), 181-185.
59. Goldstein, D. S., Holmes, C., Patronas, N. and Kopin, I. J. Cerebrospinal fluid levels of catechols in patients with neurogenic orthostatic hypotension. Clin. Sci. (Lond.), 104 (2003), 649-654.
60. Kalaria, R. N., Andorn, A. C., Tabaton, M. et al. Adrenergic receptors in aging and Alzheimer's disease: increased beta 2-receptors in prefrontal cortex and hippocampus. J. Neurochem., 53 (1989), 1772-1781.
61. Akiyama, H., Barger, S., Barnum, S. et al. Inflammation and Alzheimer's disease. Neurobiol. Aging, 21 (2000), 383-421.
62. Heneka, M. T., Galea, E., Gavriluyk, V. et al. Noradrenergic depletion potentiates betaamyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci., 22 (2002), 2434-2442.
63. White, S. R., Bhatnagar, R. K. and Bardo, M. T. Norepinephrine depletion in the spinal cord gray matter of rats with experimental allergic encephalomyelitis. J. Neurochem., 40 (1983), 1771-1773.
64. Jovanova-Nesic, K., Nikolic, V. and Jankovic, B.D. Locus coeruleus and immunity. II. Suppression of experimental allergic encephalomyelitis and hypersensitivity skin reactions in rats with lesioned locus coeruleus. Int. J. Neurosci., 68: 3-4 (1993), 289-294.
65. Zeinstra, E., Wilczak, N. and De Keyser, J. [3H]dihydroalprenolol binding to beta adrenergic receptors in multiple sclerosis brain. Neurosci. Lett., 289 (2000), 75-77.
66. Fruhstorfer, B., Mignot, E., Bowersox, S. et al. Canine narcolepsy is associatedwith an elevated number of alpha 2-receptors in the locus coeruleus. Brain Res., 500 (1989), 209-214.
67. Mignot, E., Guilleminault, C., Bowersox, S., Rappaport, A. and Dement, W. C. Role of central alpha-1 adrenoceptors in canine narcolepsy. J. Clin. Invest., 82 (1988), 885-894.
68. Mignot, E., Renaud, A., Nishino, S. et al. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology (Berl.), 113 (1993), 76-82.
69. Hornykiewicz, O. Brain monoamines and parkinsonism. Natl. Inst. Drug Abuse Res.Monogr. Ser., 3 (1975), 13-21.
70. Narabayashi, H., Kondo, T., Yokochi, F. and Nagatsu, T. Clinical effects of L-threo-3, 4 dihydroxyphenylserine in cases of parkinsonism and pure akinesia. Adv. Neurol., 45 (1987), 593-602.
71. Mizuno, Y., Kondo, T. and Mori, H. Various aspects of motor fluctuations and their management in Parkinson's disease. Neurology, 44 (1994), S29-S34.
72. Sandyk, R. Freezing of gait in Parkinson's disease is improved by treatment with weak electromagnetic fields. Int. J. Neurosci., 85 (1996), 111-124.
73. Ringendahl, H. and Sierla, T. Freezing phenomenon in Parkinson disease. Fortschr. Neurol. Psychiatr., 65 (1997), 435-445.
74. Sandyk, R. Locus coeruleus-pineal melatonin interactions and the pathogenesis of the "on-off" phenomenon associated with mood changes and sensory symptoms in Parkinson's disease. Int. J. Neurosci., 49 (1989a), 95-101.
75. Sandyk, R. Hypothalamic-locus coeruleus mechanisms in the pathophysiology of "on-off" in L-dopa treated Parkinson's disease: a hypothesis. Int. J. Neurosci., 47 (1989b), 303-308.
76. Yamazaki, M., Tanaka, C. and Takaori, S. Significance of central noradrenergic system on harmaline induced tremor. Pharmacol. Biochem. Behav., 10 (1979), 421-427.
77. Goto, S. and Hirano, A. Catecholaminergic neurons in the parabrachial nucleus of normal individuals and patients with idiopathic Parkinson's disease. Ann. Neurol., 30 (1991), 192-196.
78. Mann, D. M. and Yates, P.O. Pathological basis for neurotransmitter changes in Parkinson's disease. Neuropathol. Appl. Neurobiol., 9 (1983), 3-19.
79. Zweig, R. M., Cardillo, J. E., Cohen, M., Giere, S. and Hedreen, J. C. The locus coeruleus and dementia in Parkinson's disease. Neurology, 43 (1993), 986-991.
80. Chan-Palay, V. Depression and dementia in Parkinson's disease. Catecholamine changes in the locus coeruleus, a basis for therapy. Adv. Neurol., 60 (1993), 438-446.